Dr Robin Sanderson

 Professional experience

• More than 20 years of experience
• Consultant Haematologist, King's College Hospital NHS Foundation Trust (2019 – present)
• Consultant Haematologist, Private Care at Guy’s, London Bridge Hospital (present)
• Consultant Haematologist, Canary Wharf HCA (present)
• Consultant Haematologist, London International Patient Services at Battersea Power Station (present)
• Honorary Senior Lecturer, King's College London (2020 – present)
• Clinical Research Fellow, Bart Cancer Institute (2014 – 2019)
• Honorary Haematology Specialist Registrar, Barts Health NHS Trust (2014 – 2019)
• Transplant Fellow, St Vincent’s Public Hospital, Sydney, Australia (2014)
• Medical Bone Marrow Transplant Coordinator, King's College Hospital NHS Foundation Trust (2013 – 2014)
• South-East London Haematology Training, London Deanery (2008 – 2014)

...

 Sub-specialties

• Lymphoma
• CAR-T cells and cell therapy
• Anaemia
• Blood test
• Bone marrow cancers
• Stem cells
• Chronic lymphocytic leukaemia
• Genetics of cancer
• Haemochromatosis
• HIV
• Hodgkin's disease
• Hyperferritinaemia
• Immunotherapy
• Iron deficiency
• Low blood count
• Thrombocytopenia
• Waldenstrom’s macroglobulinaemia
• Blood disorders
• Growth factors

...

 Teaching posts

• Honorary Senior Lecturer, King's College London (2020 – present)
• Clinical Lecturer in Haemato-oncology, Barts Cancer Institute (2014 – 2019)

 Education

• Doctor of Philosophy (PhD) in CAR-T cells, Barts Cancer Institute, QMUL (2020)
• Certificate of Completion of Specialist Training (CCST) in Haematology, London Deanery (2014)
• Fellowship, Royal College of Pathologists (2013) 
• Membership, Royal College of Physicians (2007)
• Bachelor of Medicine, Bachelor of Surgery, University of Dundee (2004)
• ​Bachelor of Science, Physiology 1st Class Honours King’s College London (2001)

...

 Publications and conferences

• Dr Sanderson's published research and contributions can be viewed on his ResearchGate profile.
• Diagnosis and Management of Mantle Cell Lymphoma: A British Society of Haematology Guideline. Eyre T, Bishton M, McCulloch R, O’Reilly M, Sanderson R, Menon G, Iyengar S, Lewis D, Lambert J, Linton K, McKay P. BJ Haem 2024, 204(1).
• European CAR-T Handbook (EBMT-EHA) 2nd Edition. Chapter; Management of Cytokine Release Syndrome and HLH. Published 2025.
• Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the UK: A real-world intention-to-treat analysis. O’Reilly M, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, Besley C, Alajangi R, Creasey T, Paneesha S, Elliot J, Gonzalez Arias C, Iyengar S, Wilson MR, Delaney A, Rubio L, Lambert J, Begg K, Boyle S, Cheok KPL, Collins GP, Rossie C, Johnson R, Sanderson R.  Hemasphere 2024 13;8.
• High pre-treatment burden is the most important risk factor for infectious complications following CD19 CAR T-cell therapy for LBCL. O’Reilly M, Neill L, Collin S, Stone N, Springell D, Mensah J, Cheok K, Benjamin R, Kuhnl A, Roddie C, Sanderson R.  2024, 26(8) HemaSphere.
• Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) who were naive to Bruton Tyrosine Kinase Inhibitors (BTKi). van Meerten T, Kersten MJ, Iacoboni G, Hess G, MD; Mutsaers P, García-Sancho AM, Goy A, Giné E, Hill B, Weng WK, Dreyling M, Reagan PM, Patel K, Galal A, Herbaux C, Sanderson R, et al. Wang M. in-press 2025.
• Improvement in lymphoma CAR-T outcomes over time in the UK. S Boyle, R Sanderson, M O’Reilly, T Menne, J Norman, A Bloor, S Lugthart, S Chaganti, C Arias, C Jones, A Latif, R Benjamin, V Potter, C Roddie, A Kuhnl. Br J Haem 2024, 204(2).
• Treatment outcomes in patients with large B-cell lymphoma after progression to CAR-T. Iacoboni G, Iraola-Truchuelo J, O’Reilly M, Navarro V, Menne T et al. Sanderson R, Kuhnl A.  Hemasphere 2024 8:5.
• Real-world outcomes with CAR-T therapies in Large B cell lymphoma: A systematic review and meta-analysis. Jacobson C, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M.  Transplant Cell Ther 2024 30(1).
• Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma. Mulholland N, Chandra J, Sanderson R, Kuhnl A. Radiology. 2023 Jun;307(5): e221362.
• A national service for delivery CD19 CAR-T in large B-cell lymphoma – the UK real-world experience. Kuhnl A, Roddie C, Kirkwood A, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O’Reilly M et al. BJ Haem 2022 198; 492-502.
• Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018: Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease. O’Reilly M, Sanderson R, Wilson W, Iyengar S, Lambert J, McCulloch R, Eyre T. BJHaem, 2022: 199;1.
• CAR-T toxicity management and steroid use in high-grade B-cell lymphoma. Impact of real-world survival outcomes in the UK. Blood, 138, S1 2021. Sanderson R, Kuhnl A, Tholouli E, Menne T, Patel A, Chaganti S, Besley C, Nicholson E, Latif AL, Jones C, Neill L, Rubio L, Stenson C, Amrith M, Sharplin K, Bazin J, Cheok K, Jalowiec K, Roddie C, O’Reilly M.  Oral presentation at American Society of Hematology conference 2021.
• Human herpesvirus 6 encephalitis following axicabtagene ciloleucel treatment for refractory DLBCL. Shah M, Kuhnl A, Shields G, Sudhanva M, Metaxa V, Wong S, Yallop D, Patten P, Inam S, Hockings C, Stewart O, Benjamin R, Cuthill K, Pagliuca A, Potter V, Sanderson R.  Hemasphere 2021.
• Colitis after CAR T-cell therapy for refractory large B-cell lymphoma responds to anti-integrin therapy. Hashim A, Patten P, Kuhnl A, Ooft M, Hayee B, Sanderson R. Inflamm Bowel Dis 2020.

...

 Professional membership

• Fellow, Royal College of Pathologists (2013)
• Member, Royal College of Physicians (2007)
• American Society of Hematology
• British Society of Haematology
• European Hematology Association
• Haematology Society of Australia and New Zealand

...